BACKGROUND: Children and young adults with single-ventricle physiology have abnormal exercise capacity after the Fontan operation. A medication capable of decreasing pulmonary vascular resistance should allow improved cardiac filling and improved exercise capacity. METHODS AND RESULTS: This study was a double-blind, placebo-controlled, crossover trial conducted in children and young adults after Fontan. Subjects were randomized to receive placebo or sildenafil (20 mg three times daily) for 6 weeks. After a 6-week washout, subjects crossed over for an additional 6 weeks. Each subject underwent an exercise stress test at the start and finish of each phase. After taking sildenafil, subjects had a significantly decreased respiratory rate and decreased minute ventilation at peak exercise. At the anaerobic threshold, subjects had significantly decreased ventilatory equivalents of carbon dioxide. There was no change in oxygen consumption during peak exercise, although there was a suggestion of improved oxygen consumption at the anaerobic threshold. Improvement at the anaerobic threshold was limited to the subgroup with single left or mixed ventricular morphology and to the subgroup with baseline serum brain natriuretic peptide levels≥100 pg/mL. CONCLUSIONS: In this cohort, sildenafil significantly improved ventilatory efficiency during peak and submaximal exercise. There was also a suggestion of improved oxygen consumption at the anaerobic threshold in 2 subgroups. These findings suggest that sildenafil may be an important agent for improving exercise performance in children and young adults with single-ventricle physiology after the Fontan operation. Clinical Trial Registration- URL: http://clinicaltrials.gov. Unique identifier: NCT00507819.
RCT Entities:
BACKGROUND:Children and young adults with single-ventricle physiology have abnormal exercise capacity after the Fontan operation. A medication capable of decreasing pulmonary vascular resistance should allow improved cardiac filling and improved exercise capacity. METHODS AND RESULTS: This study was a double-blind, placebo-controlled, crossover trial conducted in children and young adults after Fontan. Subjects were randomized to receive placebo or sildenafil (20 mg three times daily) for 6 weeks. After a 6-week washout, subjects crossed over for an additional 6 weeks. Each subject underwent an exercise stress test at the start and finish of each phase. After taking sildenafil, subjects had a significantly decreased respiratory rate and decreased minute ventilation at peak exercise. At the anaerobic threshold, subjects had significantly decreased ventilatory equivalents of carbon dioxide. There was no change in oxygen consumption during peak exercise, although there was a suggestion of improved oxygen consumption at the anaerobic threshold. Improvement at the anaerobic threshold was limited to the subgroup with single left or mixed ventricular morphology and to the subgroup with baseline serum brain natriuretic peptide levels ≥100 pg/mL. CONCLUSIONS: In this cohort, sildenafil significantly improved ventilatory efficiency during peak and submaximal exercise. There was also a suggestion of improved oxygen consumption at the anaerobic threshold in 2 subgroups. These findings suggest that sildenafil may be an important agent for improving exercise performance in children and young adults with single-ventricle physiology after the Fontan operation. Clinical Trial Registration- URL: http://clinicaltrials.gov. Unique identifier: NCT00507819.
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Gira S Morchi; D Dunbar Ivy; Mark C Duster; Lori Claussen; Kak-Chen Chan; Joseph Kay Journal: Congenit Heart Dis Date: 2009-04 Impact factor: 2.007
Authors: Farah Peiravian; Ahmad A Amirghofran; Mohammad Borzouee; Gholam H Ajami; Mohammad R Sabri; Sara Kolaee Journal: Asian Cardiovasc Thorac Ann Date: 2007-04
Authors: Riad B M Hosein; Andrew J B Clarke; Simon P McGuirk; Massimo Griselli; Oliver Stumper; Joseph V De Giovanni; David J Barron; William J Brawn Journal: Eur J Cardiothorac Surg Date: 2007-01-22 Impact factor: 4.191
Authors: Guruprasad A Giridharan; Mickey Ising; Michael A Sobieski; Steven C Koenig; Jun Chen; Steven Frankel; Mark D Rodefeld Journal: ASAIO J Date: 2014 Nov-Dec Impact factor: 2.872
Authors: Robert D Tunks; Piers C A Barker; Daniel K Benjamin; Michael Cohen-Wolkowiez; Gregory A Fleming; Matthew Laughon; Jennifer S Li; Kevin D Hill Journal: Pediatr Crit Care Med Date: 2014-01 Impact factor: 3.624
Authors: Hayden J Zaccagni; Jeffrey A Alten; David C Cleveland; R Tyler Argent; Mark A Law; Ayesha S Bryant; Santiago Borasino Journal: Pediatr Cardiol Date: 2016-06-09 Impact factor: 1.655
Authors: Kalpi Desai; Christopher M Haggerty; Kirk R Kanter; Jarek Rossignac; Thomas L Spray; Mark A Fogel; Ajit P Yoganathan Journal: Interact Cardiovasc Thorac Surg Date: 2013-04-05
Authors: Ryan J Butts; Victor Zak; Daphne Hsu; James Cnota; Steven D Colan; David Hehir; Paul Kantor; Jami C Levine; Renee Margossian; Marc Richmond; Anita Szwast; Derek Williams; Richard Williams; Andrew M Atz Journal: Pediatr Cardiol Date: 2014-02-13 Impact factor: 1.655
Authors: Anastacia M Garcia; Stephanie J Nakano; Anis Karimpour-Fard; Karin Nunley; Penny Blain-Nelson; Natalie M Stafford; Brian L Stauffer; Carmen C Sucharov; Shelley D Miyamoto Journal: Circ Heart Fail Date: 2018-09 Impact factor: 8.790
Authors: Renee Margossian; Lynn A Sleeper; Gail D Pearson; Piers C Barker; Luc Mertens; Michael D Quartermain; Jason T Su; Girish Shirali; Shan Chen; Steven D Colan Journal: J Am Soc Echocardiogr Date: 2016-09-10 Impact factor: 5.251